Supports a shift away from fat-storage signalling and toward improved metabolic activity
Neuroprotective and neurorestorative effects of Thymosin Beta-4 treatment following traumatic brain injury
A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis
These studies are cited, and the researchers claims are explained below
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
It clears toxins, strengthens your immune system, protects your skin, and supports liver function